RecruitingHigh Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular Risk

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Eligible age

18+ yrs

Accepts

All genders

Locations

37 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.

Sponsor: Alnylam Pharmaceuticals

You may qualify if…

✓ Is 18 years or older for patients with established cardiovascular disease (CVD)
✓ Is 55 years or older for patients with high risk for CVD
✓ Has established CVD (defined as coronary, cerebrovascular, or peripheral artery disease) or high risk for CVD
✓ Has treated hypertension on stable therapy with at least 2 standard of care antihypertensive medications, one of which must be a thiazide, thiazide-like, or loop diuretic

You may not qualify if…

✕ Has known history of secondary hypertension
✕ Has symptomatic orthostatic hypotension
✕ Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3×upper limit of normal (ULN)
✕ Has total serum bilirubin \>1.5×ULN
✕ Has international normalized ratio (INR) \>1.5
✕ Has serum potassium \>4.8 mEq/L
✕ Has estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m\^2